Analysts think CYCC stock price could increase by 197%
Nov 26, 2024, 12:26 PM
-7.67%
What does CYCC do
Cyclacel Pharmaceuticals, based in Berkeley Heights, New Jersey, develops cancer medicines focusing on cell cycle and transcriptional regulation. Its key programs include fadraciclib and plogosertib, targeting solid tumors and hematological malignancies.
3 analysts think CYCC stock price will increase by 196.51%. The current median analyst target is $1.02 compared to a current stock price of $0.34. The lowest analysts target is $1.01 and the highest analyst target is $1.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
